| Arthritis, Psoriatic
Bimzelx vs Stelara
Side-by-side clinical, coverage, and cost comparison for arthritis, psoriatic.Deep comparison between: Bimzelx vs Stelara with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsStelara has a higher rate of injection site reactions vs Bimzelx based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Stelara but not Bimzelx, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bimzelx
Stelara
At A Glance
SC injection
Every 4-8 weeks
IL-17A and F antagonist
SC injection
Every 8-12 weeks
IL-12/23 antagonist
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Non-Radiographic Axial Spondyloarthritis
- Ankylosing spondylitis
- Hidradenitis Suppurativa
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Crohn Disease
- Ulcerative Colitis
Dosing
Psoriasis vulgaris 320 mg SC at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter; for patients weighing 120 kg or more, consider 320 mg every 4 weeks after Week 16.
Arthritis, Psoriatic, Non-Radiographic Axial Spondyloarthritis, Ankylosing spondylitis 160 mg SC every 4 weeks; for Arthritis, Psoriatic with coexistent moderate to severe plaque psoriasis, use the plaque psoriasis dosing regimen.
Hidradenitis Suppurativa 320 mg SC at Weeks 0, 2, 4, 6, 8, 10, 12, 14, and 16, then every 4 weeks thereafter.
Psoriasis vulgaris Adults <=100 kg: 45 mg SC at weeks 0 and 4, then every 12 weeks; adults >100 kg: 90 mg SC at weeks 0 and 4, then every 12 weeks; pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for 60-100 kg, 90 mg for >100 kg) SC at weeks 0 and 4, then every 12 weeks.
Arthritis, Psoriatic Adults: 45 mg SC at weeks 0 and 4, then every 12 weeks (90 mg for >100 kg with co-existent moderate-to-severe plaque psoriasis); pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for >=60 kg, 90 mg for >100 kg with co-existent plaque psoriasis) SC at weeks 0 and 4, then every 12 weeks.
Crohn Disease, Ulcerative Colitis Adults: single IV induction dose (260 mg for <=55 kg, 390 mg for >55-85 kg, 520 mg for >85 kg), followed by 90 mg SC at week 8, then every 8 weeks.
Contraindications
—
- Clinically significant hypersensitivity to ustekinumab or any excipient of STELARA
Adverse Reactions
Most common (>=1%) Upper respiratory infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, herpes simplex infections, acne, folliculitis, fatigue, diarrhea, urinary tract infection
Serious Suicidal ideation and behavior, serious infections, liver biochemical abnormalities, inflammatory bowel disease
Postmarketing Conjunctivitis, esophageal candidiasis
Most common (>=1%) Nasopharyngitis, upper respiratory tract infection, headache, fatigue, back pain, dizziness, pharyngolaryngeal pain, pruritus, injection site erythema, myalgia, depression
Serious Infections, malignancies, serious hypersensitivity reactions, posterior reversible encephalopathy syndrome (PRES), noninfectious pneumonia
Postmarketing Hypersensitivity reactions (anaphylaxis, angioedema, dyspnea, rash, urticaria), lower respiratory tract infection, PRES, interstitial pneumonia, eosinophilic pneumonia, cryptogenic organizing pneumonia, pustular psoriasis, erythrodermic psoriasis, hypersensitivity vasculitis
Pharmacology
Bimekizumab-bkzx is a humanized IgG1 monoclonal antibody that selectively binds IL-17A, IL-17F, and IL-17AF cytokines, inhibiting their interaction with the IL-17 receptor complex and suppressing the release of proinflammatory cytokines and chemokines.
Ustekinumab is a human IgG1k monoclonal antibody that binds the p40 protein subunit shared by IL-12 and IL-23, blocking their interaction with the IL-12Rb1 receptor chain and thereby suppressing downstream inflammatory signaling involved in natural killer cell activation and CD4+ T-cell differentiation and activation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bimzelx
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Stelara
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
UnitedHealthcare
Bimzelx
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (5/8)
Stelara
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Bimzelx
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Stelara
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$15/fillfill
Bimzelx BridgeCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/fillfill
Stelara withMe Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BimzelxView full Bimzelx profile
StelaraView full Stelara profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.